Athira Pharma, Inc. (ATHA) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2024. Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to modulate the neurotrophic hepatocyte growth factor (HGF) system for the treatment of neurodegenerative diseases. The company is currently pivoting its strategy following the failure of its previous lead candidate, fosgonimeton, to meet primary endpoints in the LIFT-AD Phase 2/3 trial for Alzheimer's disease. Development focus has shifted to ATH-1105, a novel small molecule for Amyotrophic Lateral Sclerosis (ALS), which completed a successful Phase 1 safety trial in November 2024. The company is actively exploring strategic alternatives, including partnerships or a sale, to maximize shareholder value.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(96.9) million | $(117.7) million |
| Operating Expenses | $100.9 million | $125.5 million |
| Cash, Cash Equivalents, and Investments | $51.3 million | $147.4 million |
| Accumulated Deficit | $(406.1) million | $(309.2) million |
| Net Cash Used in Operating Activities | $(97.2) million | $(100.8) million |
Note: The company has no product revenue and relies on cash reserves and potential financing. The decrease in net loss is primarily due to reduced R&D spend following the pause of the fosgonimeton program and a workforce reduction.
Material Changes vs. Prior Period
- Strategic Pivot: Following negative topline results for the LIFT-AD trial in September 2024, the company paused development of fosgonimeton and shifted resources to ATH-1105.
- Workforce Reduction: In September 2024, the company executed a restructuring plan terminating approximately 70% of its workforce to reduce costs and extend its cash runway. This resulted in $2.9 million in restructuring costs.
- Legal Settlements:
- Securities Class Action: A $10.0 million settlement was finalized in November 2024 (accrued in 2022/2023). The liability was paid in 2024.
- Government Investigation: The company settled a Department of Justice investigation regarding NIH grant applications for approximately $4.1 million, recorded as a legal expense in 2024 and paid in January 2025.
- Cash Position: Cash and investments decreased significantly from $147.4 million in 2023 to $51.3 million in 2024 due to operating burn and legal settlements.
Guidance, Outlook, and Risks
Outlook: Management estimates that existing cash resources ($51.3 million) are sufficient to fund operations for at least the next 12 months. The company is engaged in a strategic review process to explore partnerships, mergers, or asset sales. No specific financial guidance was provided beyond the 12-month liquidity runway.
Key Risks:
- Liquidity: The company requires substantial additional funding to continue development of ATH-1105. Failure to raise capital could force delays or termination of programs.
- Delisting Risk: The company's stock price has traded below the $1.00 minimum bid price requirement for Nasdaq listing, and the market value of listed securities has fallen below the $50 million threshold. The company received a deficiency notice from Nasdaq in October 2024.
- Development Risk: ATH-1105 is in early clinical stages; there is no guarantee it will prove effective or safe in humans.
- Legal/Reputational: Ongoing investigations by Washington State University regarding alleged research misconduct by the former CEO could impact patent validity and reputation.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $51.3 million cash balance against the burn rate, considering the paused fosgonimeton program and reduced headcount.
- Nasdaq Compliance: Monitor the company's progress in regaining compliance with Nasdaq listing standards (minimum bid price and market value) to avoid delisting.
- Strategic Alternatives: Track updates on the strategic review process (partnerships, M&A) initiated after the LIFT-AD trial failure.
- Legal Exposure: Confirm the final resolution of the DOJ settlement ($4.1 million) and monitor the outcome of the Washington State University investigation regarding former CEO Leen Kawas.
- ATH-1105 Progress: Watch for announcements regarding the design and initiation of Phase 2 trials for ATH-1105 in ALS.